Document Detail


Whole-body MRI at 1.5 T and 3 T compared with FDG-PET-CT for the detection of tumour recurrence in patients with colorectal cancer.
MedLine Citation:
PMID:  19190917     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The purpose of this study was to assess the diagnostic accuracy of whole-body MRI (WB-MRI) at 1.5 T or 3 T compared with FDG-PET-CT in the follow-up of patients suffering from colorectal cancer. In a retrospective study, 24 patients with a history of colorectal cancer and suspected tumour recurrence underwent FDG-PET-CT and WB-MRI with the use of parallel imaging (PAT) for follow-up. High resolution coronal T1w-TSE and STIR sequences at four body levels, HASTE imaging of the lungs, contrast-enhanced T1w- and T2w-TSE sequences of the liver, brain, abdomen and pelvis were performed, using WB-MRI at either 1.5 T (n = 14) or 3 T (n = 10). Presence of local recurrent tumour, lymph node involvement and distant metastatic disease was confirmed using radiological follow-up within at least 5 months as a standard of reference. Seventy seven malignant foci in 17 of 24 patients (71%) were detected with both WB-MRI and PET-CT. Both investigations concordantly revealed two local recurrent tumours. PET-CT detected significantly more lymph node metastases (sensitivity 93%, n = 27/29) than WB-MRI (sensitivity 63%, n = 18/29). PET-CT and WB-MRI achieved a similar sensitivity for the detection of organ metastases with 80% and 78%, respectively (37/46 and 36/46). WB-MRI detected brain metastases in one patient. One false-positive local tumour recurrence was indicated by PET-CT. Overall diagnostic accuracy for PET-CT was 91% (sensitivity 86%, specificity 96%) and 83% for WB-MRI (sensitivity 72%, specificity 93%), respectively. Examination time for WB-MRI at 1.5 T and 3 T was 52 min and 43 min, respectively; examination time for PET-CT was 103 min. Initial results suggest that differences in accuracy for local and distant metastases detection using FDG-PET-CT and WB-MRI for integrated screening of tumour recurrence in colorectal cancer depend on the location of the malignant focus. Our results show that nodal disease is better detected using PET-CT, whereas organ disease is depicted equally well by both investigations.
Authors:
G P Schmidt; A Baur-Melnyk; A Haug; S Utzschneider; C R Becker; R Tiling; M F Reiser; K A Hermann
Related Documents :
1545657 - Positron emission tomography: a new, precise imaging modality for detection of primary ...
15471827 - Pet/ct using 18f-fdg in suspected lung cancer recurrence: diagnostic value and impact o...
8430547 - Estimating the depth of myometrial involvement by endometrial carcinoma: efficacy of tr...
22578877 - Quantification of synovitis in the cranio-cervical region: dynamic contrast enhanced an...
16528187 - Neuropsychological dysfunction in the absence of structural evidence for cerebral ische...
12920647 - Arthritis in children: conventional and advanced imaging.
Publication Detail:
Type:  Comparative Study; Evaluation Studies; Journal Article     Date:  2009-02-04
Journal Detail:
Title:  European radiology     Volume:  19     ISSN:  1432-1084     ISO Abbreviation:  Eur Radiol     Publication Date:  2009 Jun 
Date Detail:
Created Date:  2009-05-14     Completed Date:  2009-07-22     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9114774     Medline TA:  Eur Radiol     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  1366-78     Citation Subset:  IM    
Affiliation:
Department of Clinical Radiology, University Hospitals Grosshadern, Ludwig Maximilian University Munich, Marchioninistr. 15, 81377, Munich, Germany. gerwin.schmidt@med.uni-muenchen.de
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Aged, 80 and over
Colorectal Neoplasms / diagnosis*
Female
Fluorodeoxyglucose F18 / diagnostic use*
Humans
Magnetic Resonance Imaging / methods*
Male
Middle Aged
Neoplasm Recurrence, Local / diagnosis*
Positron-Emission Tomography / methods*
Radiopharmaceuticals / diagnostic use
Reproducibility of Results
Sensitivity and Specificity
Tomography, X-Ray Computed / methods*
Whole Body Imaging / methods*
Chemical
Reg. No./Substance:
0/Radiopharmaceuticals; 63503-12-8/Fluorodeoxyglucose F18

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Aperistaltic effect of hyoscine N-butylbromide versus glucagon on the small bowel assessed by magnet...
Next Document:  Correlation of in vivo bladder blood flow measurements with tissue hypoxia.